Leerink Partnrs Analysts Boost Earnings Estimates for CLOV

Key Points

• Leerink Partners have raised their Q3 2025 earnings estimate for Clover Health Investments to (-0.03) per share, an improvement from their previous estimate of (-0.05) per share.
• The company has a consensus rating of "Hold" with an average price target of $4.03, according to data from MarketBeat.com.
• Insider trading activity has increased, with Director Anna U. Loengard acquiring 26,500 shares, representing an 852.09% increase in her position.

Clover Health Investments, Corp. (NASDAQ:CLOV - Free Report) - Research analysts at Leerink Partnrs lifted their Q3 2025 earnings per share estimates for shares of Clover Health Investments in a report issued on Monday, October 20th. Leerink Partnrs analyst W. Mayo now forecasts that the company will earn ($0.03) per share for the quarter, up from their previous estimate of ($0.05). The consensus estimate for Clover Health Investments' current full-year earnings is ($0.12) per share. Leerink Partnrs also issued estimates for Clover Health Investments' Q4 2025 earnings at ($0.06) EPS, FY2025 earnings at ($0.12) EPS, Q1 2026 earnings at $0.03 EPS, Q2 2026 earnings at $0.02 EPS, Q3 2026 earnings at $0.01 EPS, Q4 2026 earnings at ($0.03) EPS, FY2026 earnings at $0.02 EPS, FY2027 earnings at $0.07 EPS, FY2028 earnings at $0.12 EPS and FY2029 earnings at $0.19 EPS.

Several other analysts have also commented on CLOV. Canaccord Genuity Group decreased their price objective on Clover Health Investments from $4.50 to $4.10 and set a "buy" rating for the company in a report on Thursday, August 7th. Weiss Ratings reissued a "sell (d-)" rating on shares of Clover Health Investments in a research report on Wednesday, October 8th. Leerink Partners set a $3.00 target price on Clover Health Investments and gave the company a "market perform" rating in a research report on Tuesday. Finally, UBS Group cut their target price on Clover Health Investments from $4.50 to $3.00 and set a "neutral" rating on the stock in a research report on Wednesday, August 6th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $4.03.

Clover Health Investments Trading Down 4.3%

Shares of CLOV opened at $3.08 on Thursday. Clover Health Investments has a 12 month low of $2.12 and a 12 month high of $4.87. The stock has a fifty day moving average price of $2.82 and a 200-day moving average price of $3.02. The firm has a market cap of $1.58 billion, a PE ratio of -38.50 and a beta of 2.10.

Insiders Place Their Bets

In related news, Director Anna U. Loengard acquired 26,500 shares of Clover Health Investments stock in a transaction on Wednesday, August 13th. The stock was acquired at an average price of $2.59 per share, for a total transaction of $68,635.00. Following the purchase, the director owned 29,610 shares of the company's stock, valued at approximately $76,689.90. This represents a 852.09% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 24.07% of the company's stock.

Hedge Funds Weigh In On Clover Health Investments

A number of institutional investors have recently modified their holdings of CLOV. Rhumbline Advisers raised its stake in shares of Clover Health Investments by 80.5% during the 1st quarter. Rhumbline Advisers now owns 7,085 shares of the company's stock valued at $25,000 after buying an additional 3,160 shares during the last quarter. Fifth Third Bancorp purchased a new position in shares of Clover Health Investments during the 2nd quarter valued at about $28,000. Clarity Wealth Advisors LLC purchased a new position in shares of Clover Health Investments during the 2nd quarter valued at about $28,000. Alteri Wealth LLC purchased a new position in shares of Clover Health Investments during the 2nd quarter valued at about $30,000. Finally, Envestnet Asset Management Inc. purchased a new position in shares of Clover Health Investments during the 2nd quarter valued at about $31,000. Hedge funds and other institutional investors own 19.77% of the company's stock.

About Clover Health Investments

Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.